CAI FY 2024 Earnings — Caris Life Sciences, Inc. Revenue & Financial Results | Market Cap Arena

CAICaris Life Sciences, Inc.

$5B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$412M+34.7% YoY

Gross Profit

$179M43.4% margin

Operating Income

-$257M-62.4% margin

Net Income

-$282M-68.4% margin

EPS (Diluted)

$-2.70

Cash Flow

Operating Cash Flow

-$245M

Free Cash Flow

-$254M

Stock-Based Comp.

$19M

Balance Sheet

Total Assets

$344M

Total Liabilities

$2.8B

Stockholders' Equity

-$2.5B

Cash & Equivalents

$64M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$412M	$306M	+34.7%
Gross Profit	$179M	$89M	+100.2%
Operating Income	-$257M	-$320M	+19.5%
Net Income	-$282M	-$341M	+17.4%